Targeting FGL2 in glioma immunosuppression and malignant progression

8Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

Abstract

Glioblastoma (GBM) is the most malignant type of glioma with the worst prognosis. Traditional therapies (surgery combined with radiotherapy and chemotherapy) have limited therapeutic effects. As a novel therapy emerging in recent years, immunotherapy is increasingly used in glioblastoma (GBM), so we expect to discover more effective immune targets. FGL2, a member of the thrombospondin family, plays an essential role in regulating the activity of immune cells and tumor cells in GBM. Elucidating the role of FGL2 in GBM can help improve immunotherapy efficacy and design treatment protocols. This review discusses the immunosuppressive role of FGL2 in the GBM tumor microenvironment and its ability to promote malignant tumor progression while considering FGL2-targeted therapeutic strategies. Also, we summarize the molecular mechanisms of FGL2 expression on various immune cell types and discuss the possibility of FGL2 and its related mechanisms as new GBM immunotherapy.

Cite

CITATION STYLE

APA

Ma, X., Zhu, H., Cheng, L., Chen, X., Shu, K., & Zhang, S. (2022, October 13). Targeting FGL2 in glioma immunosuppression and malignant progression. Frontiers in Oncology. Frontiers Media S.A. https://doi.org/10.3389/fonc.2022.1004700

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free